Business Context and Reporting Period
Company: Ameren Corporation (AEE)
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2026
Event: Amendment to Equity Distribution Sales Agreement to increase the authorized gross sales price under the company's "at-the-market" equity program.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figures disclosed relate to the equity distribution program:
- Program Increase: $2,000,000,000
- Remaining Authorized Amount: $2,266,700,000
Material Changes
The material change reported is the expansion of the Company's equity distribution program. On July 31, 2026, Ameren delivered a notice to its sales agents and forward sellers to increase the aggregate gross sales price authorized under the program by $2.0 billion. This action was taken pursuant to the Equity Distribution Sales Agreement dated May 12, 2021, as amended.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Company has no obligation to offer or sell any common stock under the Sales Agreement. The Company reserves the right to suspend offers under the agreement at any time.
Risks/Contingencies: The filing does not disclose new risks or contingencies beyond the standard discretion regarding the execution of the equity program.
Investor Verification Checklist
- Verify the total remaining capacity of $2,266,700,000 available for issuance under the updated program.
- Confirm the list of sales agents and forward purchasers involved in the amended agreement.
- Review the legal opinion (Exhibit 5) regarding the legality of the common stock issuance.
- Note that the increase in authorization does not guarantee future stock sales or proceeds.